Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not

Summary

The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6\~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6\~8 cycles.

Conditions

• Gastric Cancer

Interventions

PROCEDURE

Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Experimental group receive HIPEC two times after laproscopic gastrectomy

Sponsors & Collaborators

• Shandong Cancer Hospital and Institute

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• Zibo Central Hospital

  collaborator OTHER_GOV

• Affiliated Cancer Hospital & Institute of Guangzhou Medical University

  collaborator OTHER

• Jinan Central Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Shandong First Medical University

  collaborator OTHER

• The First Affiliated Hospital of Nanchang University

  collaborator OTHER

• Hebei Medical University Fourth Hospital

  collaborator OTHER

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• Peking University People's Hospital

  collaborator OTHER

• Tianjin Cancer Hospital

  collaborator UNKNOWN

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Union Hospital of Huazhong University of Science and Technology

  collaborator UNKNOWN

• Zhongnan Hospital

  collaborator OTHER

• Brigham and Women's Hospital

  collaborator OTHER

• Second Xiangya Hospital of Central South University

  collaborator OTHER

• Weihai Municipal Hospital

  collaborator OTHER

• Mountain University Cancer Hospital

  collaborator UNKNOWN

• Ruijin Hospital

  collaborator OTHER

• The Affiliated Hospital of Qingdao University

  lead OTHER

Principal Investigators

• Yanbing Zhou, MD · The Affiliated Hospital of Qingdao University

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-11-20

Primary Completion

2030-12-31

Completion

2030-12-31

Countries

• China

Study Locations